| Obesity and dyslipidemia |
Isolated xanthohumol supplemented in food for 12 days at concentrations of 30 and 60mg/kg/day |
Decreasing dose-dependent effect of weight gain, plasma LDL and IL-6 concentration in mice (Miranda et al. , 2016 ) Decreased hepatic weight gain, plasma triglycerides and increased fecal excretion in mice (Yui, Kiyofuji, Osada, 2014 ) |
| Obesity and dyslipidemia |
Isolated xanthohumol supplemented at 0.05% in an atherosclerotic diet |
Reduction of cholesterol accumulation in atherosclerotic regions by inhibiting esterified cholesterol transfer protein in mice (Hirata et al. , 2012 ) |
| Obesity and dyslipidemia |
Isolated xanthohumol |
Inhibitor of adipogenesis and induction of lipolysis partially via AMP-activated protein kinase (Samuels, Shashidharamurthy, Rayalam, 2018 ). |
| Diabetes and dyslipidemia |
Xanthohumol 10mg/L + 8-prenylnaringenin 10mg/L |
Reduced fat accumulation, increased insulin sensitivity, glucose tolerance, and improved lipid profile over control (Costa et al. , 2017 ) |
| Obesity and dyslipidemia |
Extract derived from brewer's wort production residue (humolinones and iso-humolinones) |
Secretion of the gastrointestinal hormone cholecystokinin in vitro (Yamazaki et al. , 2019) and fat reduction in a double-blind clinical study (Morimoto-Kobayashi et al. , 2016) |
| Obesity and type II diabetes |
Tetra-iso-alpha-acids with different chemical substitutions supplemented in the diet |
Reduction in weight gain, normalization of insulin sensitivity markers, increase in plasma concentration of anti-inflammatory cytokines and reduction in the concentration of pro-inflammatory cytokines in mice (Everard et al. , 2012) |
| Obesity and diabetes |
Different fractions of aqueous extract of hops supplemented in the diet at 2 and 5% |
Reduction in adipose tissue gain, adipocyte diameter and decreased glucose tolerance (Sumiyoshi, Kimura, 2013 ). |
| Alzheimer's disease/neuroprotection |
Isolated xanthohumol supplemented in food |
Reduction of pro-inflammatory molecules in nervous tissue (Rancán et al. , 2017 ) |
| Stroke/neuroprotection |
Isolated xanthohumol in peritoneal application 0.2 and 0.4 mg/kg |
Reduction of infarct size in induced ischemic stroke in treated groups (Yen et al. , 2012 ). |
| Alzheimer's disease/neuroprotection |
Xanthohumol in vitro |
Reduction of oxidative stress, endoplasmic reticulum stress and chemoprotective effect against the development of Alzheimer's disease (Huang et al. , 2018). |
| Hepatoprotection |
Xanthohumol supplemented in diet 1 mg/kg/day |
Inflammation modulation and liver protector (Fernández-García et al. , 2019 ). |
| Obesity-induced dementia |
Iso-Alpha Acid Extract in diet |
Reduction of neuronal loss and hippocampus atrophy (Ayabe et al. , 2018 ) Reduced inflammation in the hippocampus and improved brain activity (Ano et al. , 2019 ). |
| Obesity-induced dementia |
Extract derived from brewer's wort production residue (humolinones and iso-humolinones). |
Improved verbal fluency and less mental fatigue than placebo in double-blind clinical trial (Fukuda et al. , 2020). |
| Anticancer |
Isolated xanthohumol |
Cytotoxicity and inhibition of proliferation in breast cancer cells (Kim; Lee; Moon, 2013). NF-kB inhibitor. Angiogenesis inhibition in pancreatic cancer (Saito et al. , 2018 ). |
| Antiviral |
Xanthohumol in peritoneal application |
Reduction of liver damage and reduction of steatosis and fibrosis caused by hepatitis C virus (Yang et al. , 2013 ) |
| Antiviral |
Xanthohumol |
Hepatitis C virus replication inhibition (Lou et al. , 2014 ) and protease inhibition related to coronavirus replication (Lin et al. , 2021 ). |
| Antibiotic |
Xanthohumol |
MIC and MIB similar to metronidazole in Clostridium difficile isolated from patients with nosocomial diarrhea (Cermak et al. , 2017 ) |
| Antibiotic |
Commercial extract of supercritical CO2, lupulone and xanthohumol. |
Inhibition and reduction of Methicillin-resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci biofilm formation (Bogdanova et al. , 2018b). |
| Antibiotic |
Hop alcoholic extract |
Inhibition and reduction of biofilm formation in gram-positive bacteria related to antibiotic-resistant skin infections (Di Lodovico et al. , 2020 ). |
| Antibiotic |
Hydroalcoholic extract of hop cones, leaves, stems and rhizomes further purified to concentrate xanthohumol, lupulone and deoxyxanthohumol |
Antibiotic effect against Leishmania mexicana , Trypanosoma brucei and methicillin-resistant S. aureus (Bocquet et al. , 2019 ). |
| Antioxidant |
Extrato feito por partição hexano e metanol. |
Fraction of hexane rich in alpha and beta acids inhibited lipid peroxidation (Kontek et al. , 2021 ). |
| Control of disease vectors |
Essential oil extract |
Toxic for mosquitoes and molluscs vectors of diseases (Bedini et al. , 2016). |